Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Boeing’s 777X To Resume Testing After Engine Inspection Halt – $BA $DIA $INVO

By John F. Heerdink, Jr.

Reportedly, Boeing (BA) resumed flight testing of its 777X jets after an inspection in October identified an engine issue. Under development since 2013, the 777X (also known as 777-9) is a larger version of the 777 wide-body jet.

Last month, when GE was reviewing a technical issue that occurred during GE9X post-certification engineering testing of the plane and made a decision with the aerospace giant to remove the engine and send it to a test facility for engineering test runs in Ohio. In April, the aerospace giant informed halt in production of the 777X through 2023, and a delay was expected in handing over the first 777X jet to 2025 from 2023.


Dow 30 component Boeing (NYSE: BA) is the world’s largest aerospace company and leading manufacturer of commercial jetliners and defense, space, and security systems. To learn more about Boeing (BA) and to track its ongoing progress please visit the Vista Partners Boeing (BA) Coverage Page.

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.


Fertility rates have hit a record low in the United States. The latest US government fertility statistics come from 2019, and they estimate there were 58.2 births year per 1,000 women of childbearing age (defined by the CDC as women between ages 15 and 44).

If you have ever struggled with infertility issues, or know someone who has, you are probably well aware of how demoralizing it can be. Imagine for a moment spending thousands of dollars and months of intensive medical procedure only to end up empty handed, exhausted, sad, and defeated because after all of that time, work, and money, you still don’t have a baby. That’s an incredibly difficult situation, and it’s becoming more common each passing year. Likewise, the need for more effective, less invasive infertility treatment options is increasing with each passing year. This is the sole focus of medtech company INVO Bioscience (NASDAQ: INVO). Learn more by reading the following story that we published recently. 

INVO Bioscience (NASDAQ: $INVO), A Company Seeking To Address A Massively Underserved Fertility Market

(Read Original Story: UPDATE 1-Boeing resumes 777X flight testing after recent engine issue in Reuters)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us